DE69836783D1 - Methode zur Behandlung des Tourette-Syndroms - Google Patents

Methode zur Behandlung des Tourette-Syndroms

Info

Publication number
DE69836783D1
DE69836783D1 DE69836783T DE69836783T DE69836783D1 DE 69836783 D1 DE69836783 D1 DE 69836783D1 DE 69836783 T DE69836783 T DE 69836783T DE 69836783 T DE69836783 T DE 69836783T DE 69836783 D1 DE69836783 D1 DE 69836783D1
Authority
DE
Germany
Prior art keywords
treatment
tourette syndrome
syndrome
disorder
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69836783T
Other languages
English (en)
Other versions
DE69836783T2 (de
Inventor
Phillip Branch Chappell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE69836783D1 publication Critical patent/DE69836783D1/de
Application granted granted Critical
Publication of DE69836783T2 publication Critical patent/DE69836783T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Hydrogenated Pyridines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
DE69836783T 1997-09-05 1998-09-04 Methode zur Behandlung des Tourette-Syndroms Expired - Fee Related DE69836783T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5798797P 1997-09-05 1997-09-05
US57987P 1997-09-05

Publications (2)

Publication Number Publication Date
DE69836783D1 true DE69836783D1 (de) 2007-02-15
DE69836783T2 DE69836783T2 (de) 2007-10-31

Family

ID=22013937

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836783T Expired - Fee Related DE69836783T2 (de) 1997-09-05 1998-09-04 Methode zur Behandlung des Tourette-Syndroms

Country Status (17)

Country Link
US (1) US6127373A (de)
EP (1) EP0901789B1 (de)
JP (1) JP3004969B2 (de)
KR (1) KR100621249B1 (de)
AT (1) ATE350037T1 (de)
AU (1) AU732157B2 (de)
CA (1) CA2246584C (de)
CY (1) CY1106402T1 (de)
DE (1) DE69836783T2 (de)
DK (1) DK0901789T3 (de)
ES (1) ES2278405T3 (de)
IL (1) IL125951A (de)
MY (1) MY122052A (de)
NZ (1) NZ331742A (de)
PT (1) PT901789E (de)
TW (1) TW448048B (de)
ZA (1) ZA988102B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
WO2004026864A1 (en) * 2002-09-17 2004-04-01 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004037820A1 (en) * 2002-10-28 2004-05-06 Warner-Lambert Company Llc Oxindole substituted piperazine derivatives
KR20060009938A (ko) * 2003-05-16 2006-02-01 화이자 프로덕츠 인코포레이티드 양극성 장애 및 연관된 증상의 치료
WO2004100992A2 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
MXPA05012325A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Procedimiento para potenciar la cognicion usando zipirasidona.
MXPA05012391A (es) * 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamiento de trastornos psicoticos y depresivos.
CA2525868A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
MA41169A (fr) * 2014-12-17 2017-10-24 Acraf Composés antibactériens à large spectre d'activité

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DE3923045A1 (de) * 1989-07-13 1991-01-17 Merck Patent Gmbh Indolderivate
US5314885A (en) * 1992-09-11 1994-05-24 Mcneilab, Inc. Cyclic benzylamino, benzylamido, and benzylimido antipsychotic agents

Also Published As

Publication number Publication date
IL125951A0 (en) 1999-04-11
TW448048B (en) 2001-08-01
CA2246584A1 (en) 1999-03-05
NZ331742A (en) 2000-07-28
EP0901789B1 (de) 2007-01-03
CA2246584C (en) 2002-09-24
KR19990029571A (ko) 1999-04-26
PT901789E (pt) 2007-03-30
JPH11180874A (ja) 1999-07-06
DK0901789T3 (da) 2007-04-10
MY122052A (en) 2006-03-31
KR100621249B1 (ko) 2006-10-24
AU732157B2 (en) 2001-04-12
CY1106402T1 (el) 2011-04-06
DE69836783T2 (de) 2007-10-31
JP3004969B2 (ja) 2000-01-31
IL125951A (en) 2003-09-17
US6127373A (en) 2000-10-03
ATE350037T1 (de) 2007-01-15
EP0901789A1 (de) 1999-03-17
AU8310698A (en) 1999-03-18
ES2278405T3 (es) 2007-08-01
ZA988102B (en) 2000-03-22

Similar Documents

Publication Publication Date Title
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DE69736183D1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
ATE374029T1 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
PT768086E (pt) Tratamento de tinido utilizando agentes neuroprotectores
CY1106402T1 (el) Μεθοδος θepαπειας του συνδρομου tourette
DE69929787D1 (de) Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE249830T1 (de) Die verwendung von r (+)- g(a)-(2,3- dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol zur behandlung von obstruktive schlafapnoe
CA2387394A1 (en) Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
ATE374021T1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post- chirurgischen schmerzbehandlung
DE69800906T2 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
DE60206391D1 (de) Verwendung von thiazolderivaten zur herstellung eines medikaments zur behandlung von chronischen obstruktiven atemwegserkrankungen
RU2001129744A (ru) Способ лечения бациллярных форм туберкулеза легких
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler
DE69116187D1 (de) Verwendung eines Dihydropyridins zur Verbesserung der Blutzirkulation des inneren Ohres
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee